Table 1 Selected characteristics of 437 breast cancer patients of the ISE cohort, additionally stratified by clinically important levels of cancer-related fatigue (CRF; ≥39 scores, based on the EORTC QLQ-C30) at the end of radiotherapy
Characteristic | No CRF, N = 2731 | CRF, N = 1641 | Overall, N = 4371 |
|---|---|---|---|
Deceased From Any Cause | |||
10-year Follow-Up | 25 (9.2%) | 27 (16.5%) | 52 (11.9%) |
15-year Follow-Up | 45 (16.5%) | 41 (25%) | 86 (19.7%) |
Age (years) | |||
Mean (SD) | 60 (9) | 61 (9) | 61 (9) |
Range | 26–87 | 38–85 | 26–87 |
Body Mass Index | |||
< 25 kg/m² | 132 (49%) | 65 (40%) | 197 (45%) |
25–30 kg/m² | 113 (42%) | 70 (43%) | 183 (42%) |
> 30 kg/m² | 27 (9.9%) | 28 (17%) | 55 (13%) |
Missing | 1 | 1 | 2 |
Tumour Size | |||
T0 | 1 (0.4%) | 0 | 1 (0.2%) |
T1 | 181 (66%) | 112 (68%) | 293 (67%) |
T2 | 64 (23%) | 41 (25%) | 105 (24%) |
T4 | 1 (0.4%) | 0 | 1 (0.2%) |
TX | 0 | 1 (0.6%) | 1 (0.2%) |
In Situ | 26 (9.5%) | 10 (6.1%) | 36 (8.2%) |
Nodal Status | |||
N0 | 208 (76%) | 125 (76%) | 333 (76%) |
N1 | 38 (14%) | 27 (16%) | 65 (15%) |
N2 | 1 (0.4%) | 1 (0.6%) | 2 (0.5%) |
NX | 26 (9.5%) | 11 (6.7%) | 37 (8.5%) |
Histological Type | |||
In Situ | 28 (10%) | 9 (18%) | 37 (8.5%) |
Invasive Ductal | 152 (56%) | 100 (61%) | 252 (58%) |
Invasive Lobular | 57 (21%) | 32 (20%) | 89 (20%) |
Other | 36 (13%) | 23 (14%) | 59 (14%) |
Histological Grading | |||
Grade 1 | 50 (19%) | 29 (18%) | 79 (19%) |
Grade 2 | 169 (64%) | 101 (63%) | 270 (64%) |
Grade 3 | 46 (17%) | 30 (19%) | 76 (18%) |
Missing | 8 | 4 | 12 |
Hormone Receptor Status (ER/PR)* | |||
Negative | 32 (12%) | 10 (6.1%) | 42 (9.7%) |
Positive | 240 (88%) | 153 (94%) | 393 (90%) |
Missing | 1 | 1 | 2 |
Total Radiotherapy Dose | |||
50–60.4 Gy | 150 (55%) | 104 (63%) | 254 (58%) |
> 60.4 Gy | 123 (45%) | 60 (37%) | 183 (42%) |